Nippon Shinyaku Co., Ltd. and Janssen Pharmaceutical K.K. to Jointly Develop New Oral Immediately-Release Painkiller

24-Feb-2005

Nippon Shinyaku Co., Ltd., Janssen Pharmaceutical K.K. and Grunenthal GmbH have concluded a co-development agreement to jointly develop and commercialize in Japan an oral painkiller, Tramadol Hydrochloride Immediate-Release Formulation as of February 14, 2005.

Tramadol hydrochloride, a compound discovered by Germany-based Grunenthal, came to the German market in 1981 as an oral immediate-release formulation. Since then, various formulations containing tramadol hydrochloride have been launched in more than 100 countries worldwide.

Nippon Shinyaku concluded a license agreement for tramadol hydrochloride immediate-release formulation in 1996 and has proceeded with its clinical development for cancer pain since then. Under this tripartite agreement, Janssen Pharmaceutical will develop this formulation for treating non-malignant pain. Nippon Shinyaku and Janssen Pharmaceutical plan to develop its indication separately, but submit for its NDA application simultaneously and distribute it under different trademarks.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!